Srikripa Devarakonda

Can you remind us of data that suggests any synergistic benefit? And given how well ka is entrenched in the myelofibrosis market

I wanted to just get your expectations for provercitinib in asthma with the phase two readout coming up

is there a rationale to develop both in suboptimal responders as well as in rux naive patients? Or do you see it as a better strategy to focus on one

Can you talk about the patient population where you're seeing increased uptake? And also given the footprint you have established here

Can you talk about the patient population where you're getting uptake and what are the -- what the expectations are in terms of growth?